Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.71 |
| ▸ | PGR | P06401 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875309 | 1.00 | PFKFB3 (0.71) | PFKFB3PGRMEN1KMT2APOLB | |
| SCHEMBL29369447 | 1.00 | PFKFB3 (0.71) | PFKFB3PGRMEN1KMT2APOLB | |
| SCHEMBL8251165 | 0.94 | PFKFB3 (0.67) | PFKFB3PGRMEN1KMT2APOLB | |
| SCHEMBL2828714 | 0.88 | MEN1 (0.74) | PGRMEN1KMT2AMAPTTHRB | |
| SCHEMBL5329565 | 0.87 | PGR (0.80) | PGRMEN1KMT2AMAPTPKM | |
| SCHEMBL17331335 | 0.87 | POLB (0.78) | PFKFB3MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL894613 | 0.86 | POLB (0.82) | PFKFB3MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL787825 | 0.85 | PFKFB3 (0.79) | PFKFB3PGRMEN1KMT2APOLB | |
| SCHEMBL788010 | 0.85 | PFKFB3 (0.83) | PFKFB3PGRMEN1KMT2APOLB | |
| SCHEMBL29561210 | 0.85 | POLB (0.71) | PFKFB3PGRMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250258104-A1 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | SCANWELL HEALTH INC (US) | 2025-08-14 | — | — | US | claimed |
| US-12235217-B2 | Diagnostic test kits for sample preparation and analysis | SCANWELL HEALTH, INC. (US) | 2025-02-25 | — | — | US | claimed |
| EP-4058775-A1 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | Scanwell Health, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114981637-A | Diagnostic test kit for sample preparation and analysis | 斯肯威尔健康公司 | 2022-08-30 | — | — | CN | claimed |
| US-20210231574-A1 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | SCANWELL HEALTH, INC. | 2021-07-29 | — | — | US | claimed |
| WO-2021097343-A1 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | SCANWELL HEALTH, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| US-20250258104-A1 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | SCANWELL HEALTH INC (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4587481-A1 | PROCESS FOR CONJUGATION OF HYALURONIC ACID AND CONJUGATES OF HYALURONIC ACID SO OBTAINED | GLYCOCORE PHARMA S.r.l. (IT) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025056689-A1 | ELECTROCHEMICAL DETECTION OF MONOCHLORAMINE AND/OR AMMONIA | PALINTEST LTD (GB) | 2025-03-20 | — | — | WO | disclosed |
| US-12235217-B2 | Diagnostic test kits for sample preparation and analysis | SCANWELL HEALTH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2024057154-A1 | PROCESS FOR CONJUGATION OF HYALURONIC ACID AND CONJUGATES OF HYALURONIC ACID SO OBTAINED | GLYCOCORE PHARMA S.R.L. (IT) | 2024-03-21 | — | — | WO | disclosed |
| EP-4058775-A1 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | Scanwell Health, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-114981637-A | Diagnostic test kit for sample preparation and analysis | 斯肯威尔健康公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD | 2010-06-10 | — | — | US | disclosed |
| US-7723538-B2 | enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid | HOFFMANN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| CN-101189210-A | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | CN | disclosed |
| EP-1891001-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131452-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | PFKFB3 509/4885PGR 4545/4885MEN1 4442/4885 |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | PFKFB3 509/4885PGR 4545/4885MEN1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.